Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24315682 | 0.97 | L3MBTL1 (0.48) | L3MBTL1LMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL27010256 | 0.87 | ALDH1A1 (0.56) | LMNASMN1; SMN2ALDH1A1POLBMAPK1 | |
| SCHEMBL26620050 | 0.87 | L3MBTL1 (0.51) | L3MBTL1LMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL26620370 | 0.84 | L3MBTL1 (0.52) | L3MBTL1LMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL27010386 | 0.84 | ALDH1A1 (0.57) | LMNASMN1; SMN2ALDH1A1POLBMAPK1 | |
| SCHEMBL27010244 | 0.80 | TSHR (0.53) | L3MBTL1LMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL24315790 | 0.79 | PTGDR2 (0.43) | L3MBTL1SMN1; SMN2ALDH1A1POLBATM | |
| SCHEMBL27010315 | 0.79 | L3MBTL1 (0.51) | L3MBTL1LMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL24317329 | 0.79 | TSHR (0.48) | L3MBTL1LMNASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL24317836 | 0.78 | L3MBTL1 (0.48) | L3MBTL1LMNASMN1; SMN2NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | L3MBTL1 3664/4885LMNA 3978/4885SMN1; SMN2 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.